Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible streptococcus pneumoniae

Journal of Infectious Diseases

Volumn 211, Issue 7, 2015, Pages 1144-1153

  Dagan, Ron ^a,b   Juergens, Christine ^c   Trammel, James ^d   Patterson, Scott ^c   Greenberg, David ^a,b   Givon Lavi, Noga ^a,b   Porat, Nurith ^a,b   Gurtman, Alejandra ^c   Gruber, William C ^c   Scott, Daniel A ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c PFIZER INC   (United States)

^d SYNEOS HEALTH   (United States)

Author keywords

antibiotic nonsusceptibility; nasopharyngeal colonization; pneumococcal conjugate vaccine; Streptococcus pneumoniae

Indexed keywords

CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN DERIVATIVE; PENICILLIN PLUS ERYTHROMYCIN; PNEUMOCOCCUS VACCINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; PREVENAR13; VACCINE;

ANTIBIOTIC NONSUSCEPTIBLE STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DISK DIFFUSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPSILOMETER TEST; FEMALE; HUMAN; HUMAN EXPERIMENT; INFANT; ISRAEL; MALE; MINIMUM INHIBITORY CONCENTRATION; NASOPHARYNGEAL ASPIRATION; NONHUMAN; NORMAL HUMAN; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; DRUG EFFECTS; IMMUNOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTIONS; SEROTYPING; STANDARDS;

ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; RESPIRATORY TRACT INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84927722408     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu576     Document Type: Article

References (40)

1. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007; 82:93-104.
2. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibioticnonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205:401-11.
3. Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012; 30:2728-37.
4. Jinno S, Jacobs MR. Pneumonia due to drug-resistant Streptococcus pneumoniae. Curr Infect Dis Rep 2012; 14:292-9.
5. Link-Gelles R, Thomas A, Lynfield R, et al. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis 2013; 208:1266-73.
6. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63.
7. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010; 28:4249-59.
8. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009; 199:776-85.
9. Nzene S, Klugman K, Madhi SA. The potential impact of the 13-valent conjugate pneumococcal vaccine on antibiotic resistance in pneumococci. South Afr J Epidemiol Infect 2011; 26:253-8.
10. Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57:952-62.
11. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007; 45:1225-33.
12. Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 2011; 29:7207-11.
13. NCCLS Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. Document M100-S18.Wayne, PA: Clinical and Laboratory Institute, 2008.
14. CDC. Pneumococcal disease: drug resistance. Atlanta, GA: Centers for Disease Control and Prevention. http://www.cdc.gov/pneumococcal/drug-resistance.html. Accessed 11 April 2014.
15. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet InfectDis 2004; 4:144-54.
16. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009; 124:e1-11.
17. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5:83-93.
18. Grijalva CG, Pelton SI. A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children. Curr Opin Pediatr 2011; 23:98-104.
19. Ercibengoa M, Arostegi N, Marimon JM, Alonso M, Perez-Trallero E. Dynamics of pneumococcal nasopharyngeal carriage in healthy children attending a day care center in northern Spain. Influence of detection techniques on the results. BMC Infect Dis 2012; 12:69.
20. Smith T, Lehmann D, Montgomery J, Gratten M, Riley ID, Alpers MP. Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children. Epidemiol Infect 1993; 111:27-39.
21. Juergens C, Patterson S, Trammel J, et al. Functional antibody responses to 13-valent versus 7-valent pneumococcal conjugate vaccine (PCV13; PCV7): a randomized, double-blind trial. Presented at: 31st Annual Meeting of the European Society for Paediatric Infectious Diseases, Milan, Italy, 2013.
22. Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 2005; 192:367-76.
23. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9:185-94.
24. World Health Organization. Pneumococcal vaccines, WHO position paper-2012. Wkly Epidemiol Rec 2012; 87:129-44.
25. Dagan R, Givon-Lavi N, Greenberg D. A prospective study to evaluate Streptococcus pneumoniae nasopharyngeal acquisition (SPNA) in the first 30 months of life following a 3-dose primary pneumococcal conjugate vaccine (PCV7) regimen: Effect of a booster dose at 12 months of age. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009.
26. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29:9127-31.
27. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203-7.
28. Singleton R, Wenger J, Klejka JA, et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J 2013; 32:257-63.
29. O'Brien KL. PCV13 impact evaluations: the obvious and the unpredicted. Pediatr Infect Dis J 2013; 32:264-5.
30. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis 2013; 19: 1074-83.
31. Plosker GL. 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr Drugs 2013; 15:403-23.
32. Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011. Pediatr Infect Dis J 2013; 32:656-61.
33. Angoulvant F, Levy C, Varon E. Pneumococcal pneumonia in children: a French prospective study in the era of 13 valent pneumococcal conjugate vaccines implementation in France. Presented at: 31st Annual Meeting of the European Society for Paediatric Infectious Diseases, Milan, Italy, 2013.
34. Diel M, Laurenz M, Krause K. Impact of pneumococcal conjugate vaccines on pneumonia among children in Germany. Presented at: 31st Annual Meeting of the European Society for Paediatric Infectious Diseases, Milan, Italy, 2013.
35. Simonson L, Klugman K, Taylor RJ, Schuck C, Lustig R, Haber M. Reductions in invasive and non-invasive pneumo-related US hospital admissions only two years after PCV13 introduction: evidence of substantial direct and indirect (herd) benefits. Presented at: IDWeek, San Francisco, CA, 2013.
36. Dagan R, Greenberg D, Leibovitz E, Raiz S, Givon-Lavi N. Trends in serotype-specific pneumococcal carriage in children visiting emergency room (PER) post PCV7 and PCV13 introduction correlate with trends in serotype-specific otitis media incidence (OM). Presented at: IDWeek, San Francisco, CA, 2013.
37. Zhao AS, Boyle S, Butrymowicz A, Engle RD, Roberts JM, Mouzakes J. Impact of 13-valent pneumococcal conjugate vaccine on otitis media bacteriology. Int J Pediatr Otorhinolaryngol 2014; 78:499-503.
38. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297-301.
39. Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 2006; 5:651-67.
40. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012; 11:841-55.